Deep Health AI India Approves ₹35 Crore Capital Boost for AI Health Tech

TECH
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Deep Health AI India Approves ₹35 Crore Capital Boost for AI Health Tech
Overview

Deep Health AI India Limited shareholders overwhelmingly approved a ₹35 crore increase in authorized share capital, raising it to ₹50 crore, and a related update to its Memorandum of Association. The postal ballot saw 99.16% of votes in favour, reflecting strong confidence in the company's AI health-tech ventures.

Deep Health AI India Boosts Capital After Shareholder Vote

Deep Health AI India Limited has received overwhelming support from its shareholders to increase its authorized share capital. A postal ballot process concluded with 99.16% of votes cast in favour of raising the capital by ₹35 crore and updating the company's Memorandum of Association (MoA).

A total of 860,035 shares voted for the resolution, with only 7,265 shares voting against it.

Shareholders Approve Capital Boost

Deep Health AI India Limited successfully concluded its postal ballot for shareholders to approve the company's plan to increase authorized share capital.

The resolution passed with 99.16% of votes cast. This approval allows the company to increase its authorized share capital from ₹15 crore to ₹50 crore, a ₹35 crore expansion.

This capital enhancement requires an update to the Capital Clause of the company's Memorandum of Association (MoA).

The e-voting period for the postal ballot ran from February 27, 2026, to March 28, 2026. The eligibility cut-off date for voting was February 20, 2026.

Funding AI Health Tech Growth

This shareholder approval provides Deep Health AI India Limited with greater financial flexibility to achieve its strategic goals.

It is essential for funding the company's ongoing expansion into the AI-driven healthcare technology sector, particularly for its 'Deep Health AI' wellness platform.

Background: From Jewellery to AI Health

Deep Health AI India Limited, previously known as Deep Diamond India Limited, is undergoing a significant transformation.

Founded in 1994 and formerly involved in the jewellery business, the company has shifted its focus to AI-powered health-tech.

It launched its 'Deep Health AI' platform in late 2025, which offers contactless wellness assessments using smartphone facial scans.

This pivot followed a ₹39.97 crore rights issue in October 2025. Notably, this rights issue saw a deviation, with ₹22.50 crore of the funds diverted from planned acquisitions to equity investments. This move required subsequent shareholder approval and drew attention from auditors.

Key Changes Following Approval

  • The company's authorized share capital will officially rise from ₹15 crore to ₹50 crore.
  • The Memorandum of Association will be updated to reflect this new capital structure.
  • This move provides a clearer financial path for growth initiatives and future funding needs.

Challenges Ahead

While shareholders have approved the capital increase, past concerns about fund utilization remain relevant. A significant deviation in the rights issue proceeds, where ₹22.50 crore was diverted to investments instead of acquisitions, was reported. This led to auditor remarks and required National Company Law Tribunal (NCLT) extensions for planned acquisitions.

Execution risk also exists for the 'Deep Health AI' platform's growth and market penetration, especially in the competitive digital health sector.

The company's historical jewellery business and its recent 8.23% stake acquisition in Exxaro Tiles Limited indicate a diversification strategy, which carries the risk of managing different types of businesses.

Comparison to AI Health Peers

Indian AI healthcare companies like Qure.ai, SigTuple, and Niramai primarily focus on clinical diagnostics and medical image analysis. Deep Health AI's 'Deep Health AI' platform offers a different approach.

Its focus is on preventive wellness screening using facial scan AI, aiming for broad accessibility rather than specialized clinical diagnostics.

This positions the company in the growing digital wellness and preventive health tech market, distinct from peers in more specialized medical AI solutions.

Key Figures and Timeline

  • The authorized share capital is proposed to increase from ₹15,00,00,000 to ₹50,00,00,000, a 233.33% rise. (Context: Q3 FY26 filing).
  • Shareholder approval for fund utilization deviations in the rights issue was secured on January 22, 2026. (Context: Q3 FY26).

Future Watchpoints

  • How the increased authorized capital will be used to expand the 'Deep Health AI' platform.
  • Progress on future acquisitions or investments, particularly concerning the Exxaro Tiles stake.
  • Performance updates and market adoption figures for the 'Deep Health AI' wellness platform.
  • Any further disclosures concerning the Oasis Ceramics acquisition and NCLT proceedings.
Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.